Associated Genetic Biomarkers
NCI Definition: A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008) 
There are 5 clinical trials for essential thrombocythemia, of which 1 is open and 4 are completed or closed. Of the trials that contain essential thrombocythemia as an inclusion criterion, 1 is phase 1/phase 2 (0 open), 3 are phase 2 (1 open), and 1 is phase 3 (0 open).
JAK2 is the most frequent gene inclusion criterion for essential thrombocythemia clinical trials .
Img-7289, aspirin, and hydroxyurea are the most common interventions in essential thrombocythemia clinical trials.
Significant Genes in Essential Thrombocythemia
JAK2 is an inclusion eligibility criterion in 3 clinical trials for essential thrombocythemia, of which 0 are open and 3 are closed. Of the trials that contain JAK2 status and essential thrombocythemia as inclusion criteria, 1 is phase 1/phase 2 (0 open), 1 is phase 2 (0 open), and 1 is phase 3 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.